CMS Defends Oral ESRD Drug Inclusion In Proposed Bundling Rule
Executive Summary
In anticipation of objections to its proposal to include oral end-stage renal disease drugs currently covered under Medicare Part D in bundled payments for ESRD services, CMS offered an extensive justification for the action
You may also be interested in...
Amgen Reflects Relief From Bundling Rules, Optimistism About Prolia
Oral drugs are ruled exempt until 2014 from a new dialysis payment plan, and hopes are high for an osteoporosis drug to become a cancer blockbuster.
CMS Delays Inclusion Of Oral-Only ESRD Drugs In Final Bundled Payment Rule For Medicare
Inclusion of oral-only drugs in bundled payment will be delayed until 2014, allowing CMS to address pricing and data issues, but the decision does not alter the agency's interpretation that oral-only drugs should be a part of the bundle.
CMS Begins National Coverage Determination Process For ESAs In The Renal Setting
The opening of a national coverage analysis comes with a public request for CMS to establish Medicare coverage limitations for ESA use in pre-dialysis and dialysis renal disease patient populations.